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ABSTRACT 
Over 200,000 people in the United States are diagnosed annually with malignant 
brain tumors.  Current therapeutic methods prove ineffective at treating this type of cancer 
due to the inability to selectively target cancer cells.  Research has shown that brain cancer 
cells are heavily dependent on the sodium-proton exchanger (NHE) and sodium-calcium 
exchanger (NCX) due to their increased metabolic activity.  Inhibiting these proteins disrupts 
pH and ion balances within cancer cells while leaving healthy cells unaffected, leading to 
selective glial cell death.  Therefore, NHE and NCX inhibition allow for selective targeting 
of brain cancer cells.  The challenge that remains in using these inhibitors as a treatment is 
effectively delivering them to poorly vascularized tissues.  As part of our target-specific 
approach to treating brain cancer, we have synthesized analogs of cariporide, a potent NHE 
inhibitor, to address these challenges.  The present thesis will discuss our efforts towards the 
preparation of our analogs. 
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CHAPTER 1: INTRODUCTION 
1.1 The Sodium-Proton Exchanger 
The Sodium-Proton Exchanger (NHE) is a cell surface ion exchanger that allows 
sodium (Na
+
) ions to be transferred into the cell and proton/hydrogen (H
+
) ions to move out 
of the cell in a 1:1 ratio [1, 2].  In general, the NHE is a transport protein that works 
according to the concentration gradients of the ions, with the ions flowing from areas of 
higher concentration to areas of lower concentration.  More specifically, NHE works as an 
antiporter by moving the Na
+
 and H
+
 ions in opposite directions across the cell membrane 
through the use of the thermodynamically favorable transfer of the Na
+
 ions from areas of 
high concentration outside of the cell to areas of low concentration inside the cell (Figure 1).  
Through this mechanism, NHE can move the H
+
 ions across the cell membrane without the 
consumption of energy in the form of adenose triphosphate (ATP), the form of energy used 
by cells [2].  In the majority of cases, NHEs are used to transport H
+
 ions out of the cell and 
Na
+
 ions into the cell.  Because of this, NHE function is strongly dependent on the 
concentration of Na
+
 ions outside the cell [1].  However, NHE can also work in reverse, 
allowing H
+
 ions to enter the cell and Na
+
 ions to exit the cell [2]. 
Under anaerobic conditions (i.e., stroke, heart attack), there is a shift from oxidative 
to nonoxidative glycolysis to meet the cells’ energy needs [1].  Nonoxidative glycolysis leads 
to an intracellular accumulation of lactic acid (Figure 1).  The pH decrease activates the NHE 
which decreases the excess intracellular H
+ 
concentration.  However, the concomitant Na
+
 
ion concentration increase inside the cell is presumed to activate the sodium-calcium 
exchanger (NCX).  NCX deals with the excess Na
+ 
ions, but cause intracellular Ca
2+
 ion 
accumulation, which leads to irreversible cell damage.  According to this ‘coupled 
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exchanger’ theory, NHE initiates the sequence of physiological events that lead to cell 
damage under anaerobic conditions. 
 
Figure 1. Ion transporter activation during ischemia-reperfusion (I/R) injury 
 
NHE proteins were first discovered in 1976 by Murer et al. [3] and can be found in 
virtually all vertebrates [4].  Currently, seven different isoforms (NHE1-NHE7), of the 
sodium-proton exchanger have been identified [2], occurring in every tissue type found in the 
human body [1, 2].  These seven isoforms share a general structure that contains about 800 
amino acids with between 20 and 70% of the amino acid sequences being identical.  The 
differentiation among the NHE isoforms allows them to accommodate the specific needs of 
their resident tissues [5].  Of the seven isoforms, NHE1 is the most common and is found in 
all tissue types, acting as a sort of “housekeeper,” maintaining the cell in its proper state [1].    
NHEs perform a number of functions for the cell, including regulating both pH and 
volume and stimulating cell growth and proliferation.  Through the transfer of H
+
 ions, NHEs 
can maintain the optimal intracellular pH [4].  Normal brain cells function best at 
physiological pH of about 6.99-7.05 [6].  NHEs, by working on a gradient, are some of the 
quickest and most energy efficient ways for a cell to maintain pH.  Cells that lack NHEs are 
particularly susceptible to acidosis, which is a large increase in the intracellular acidity [5] 
and can be fatal to the cells. 
 NHEs are also important in the regulation of cell volume through intrusion of Na
+
 
ions.  Because the Na
+
 ion is so much larger than the H
+
 ion, the cell expands as sodium ions 
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enter and protons exit, allowing the cell to maintain normal volume when exposed to 
increases or decreases in extracellular water levels [5], helping the cell to maintain a healthy 
volume.   
Finally, NHEs are important in the stimulation of cell growth and proliferation in 
cells, even to the point of a “proliferative advantage” [6].  Cell proliferation is activated by 
increasing intracellular pH through the stimulation of NHE by protein growth factors [4].  
Furthermore, the increase in pH (thus basicity) of cells through NHE activation allows the 
cells to divide and grow at higher rates than cells lacking NHE, giving these cells a 
“proliferative advantage” [6].   
In order for the NHEs to work, however, they must first be activated.  This activation 
can come from a number of sources.  Obviously, NHEs react to changes in the pH of the cell, 
responding quickly to any drops in the pH below a certain standard level that depends on cell 
type [1].  In this way, they are able to maintain the necessary physiological pH.  Alternately, 
NHEs may be activated by a number of extrinsic factors including hormones and growth 
factors [5].  In doing so, the cell can initiate cell growth and reproduction in order to heal, 
maintain, or expand current tissue. 
1.2 Glioma Cells 
Malignant gliomas make up “65% of all primary brain tumors,” making them the 
most common and deadliest of all brain cancers [7].  Currently, there is no cure for malignant 
gliomas due to the ineffectiveness of current therapies, with the median survival time for 
patients being only 9 to 12 months after diagnosis [8].  
In the human brain, normal brain cells (e.g., astrocytes), maintain their pH through a 
number of ion exchangers, such as the “Na
+
/H
+
 exchanger (NHE1), the electrogenic Na
+
- 
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HCO3
-
 cotransporter, the Na
+
-dependent and Na
+
 independent Cl
-
/HCO3
-
 exchangers, H
+
-
lactate symporter, and the vacuolar type H
+
-ATPase” [6].  However, glioma cells rely upon 
NHE1 isoform to a much greater extent than any other pH regulating mechanism [6, 9], 
causing the impact of the other mechanisms to be minimal.  This increase in NHE1 activity 
in glioma cells is due to a number of factors, including the need for an increased pH to 
promote cell proliferation and an increased dependence upon nonoxidative glycolysis, 
leading to lactic acid production [7].   Thus, while normal brain cells display almost no use of 
the NHE1 at physiological pH [9], malignant glioma cells, which exist in hypoxic, acidotic 
environments, display an overactivation of the NHE1 isoform.  With no oxygen present, 
glioma cells cannot perform normal glycolysis, and thus depend on nonoxidative glycolysis, 
which produces lactic acid (as a by-product) increasing the concentration of H
+
 ions in the 
cell [7].   
Under nonoxidative glycolysis conditions, the need to deplete this acid build-up leads 
to overactivation of the NHE in gliomas.  This subsequent extrusion of hydrogen ions causes 
the exterior of the cell to become acidified quickly, causing the extracellular regions of 
glioma tumors to be much more acidic than the extracellular regions of normal tissues.  
Because of this, it has been shown that the extracellular pH is between 6.5-6.9 for glioma 
tumors, as opposed to 7.0-7.5 for normal cells [6].  Paradoxically, the internal pH of glioma 
cells has been measured to be between 7.12-7.24, which is more alkaline than that of normal 
cells, which have normal pH between 6.99-7.05 [6].  Through these studies, it has been 
determined that this difference is due to the need for a higher internal pH for cellular 
proliferation, although McLean et al. state that “there is increasing evidence that maintenance 
of the extracellular environment contributes to tumor growth and invasion as well” [6].  
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Therefore, by overactivating the NHE1 isoform, glioma cells are able to reproduce, grow, 
metastasize, and invade new tissues better than normal cells. 
This proliferative advantage, however, is not the only reason that brain cancer is so 
difficult to cure.  A number of other factors contribute to this challenge.  First of all, the 
structure of glioma tumors makes them very hard to treat.  As the tumor forms and its size 
increases, the peripheral regions of the tumor become highly vascularized and proliferative 
while the interior of the tumor becomes more and more anaerobic with proliferative cells 
scattered throughout the necrotic interior [7].  The outside cells of the tumor can be killed 
using traditional chemotherapy and radiotherapy.  However, the lack of oxygen in malignant 
glioma tumor centers inhibits the formation of radicals during radiotherapy and 
chemotherapy, and thus there is no reactive disruption of the DNA to kill the cell [7] leaving 
the interior regions of the tumor unaffected by these treatments.  Instead, the increase in 
nonoxidative glycolysis in these anaerobic areas allows the NHEs and other ion exchangers 
to keep the cells proliferating [10].  Therefore, while the highly vascularized outside portions 
of the tumor are easily killed through the conventional therapies [7], the interior cells are not 
affected, allowing the tumor to continue to grow even after the peripherial cells are killed.   
Similarly, the location of the glioma tumors in the body presents further therapeutic 
challenges.  Current chemo- and radiotherapies do not differentiate between healthy and 
cancerous cells, killing both equally.  In many tissues, this practice is acceptable because the 
surrounding tissues can proliferate to heal that region.  However, brain cells regenerate at a 
much slower rate, if at all, than normal body tissues.  Therefore, key motor skills or other 
problems could occur through the death of astrocytes surrounding the glioma tumor, making 
the use of these therapies in brain cancer patients counterproductive. 
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1.3 NHE Inhibitors 
In the brain, normal astrocytes display almost no change in pH while gliomas show a 
marked decrease in pH upon NHE inhibition [6].  This difference is due to the pH regulatory 
mechanism utilized by each type of cell.  Since glioma cells are producing large amounts of 
acid and depend heavily on the NHE1 isoform, the inhibition of the NHE1 isoform greatly 
reduces the ability of glioma cells to extrude protons, which consequently decreases their 
intracellular pH (and thus disrupt nonoxidative glycolysis).  Meanwhile, normal astrocytes do 
not produce large amounts of acid and do not rely on NHE.  Thus, NHE inhibitors affect the 
glioma cells adversely while not harming the normal astrocytes [6].  Furthermore, it is 
“generally recognized that cancer cells cannot survive for long below certain low 
[intracellular pH] conditions, either because of triggering of the apoptotic pathway or 
because of the additional shutting down of glycolysis…” [9].   
Currently, there are five classifications of NHE inhibitors including the 
aroylguanidines, heteroaroylguanidines, spacer-stretched aroylguanidines, the non-acyl 
guanidines, and the non-guanidine NHE inhibitors (Figure 2) [11].  
Four of the five classifications of NHE inhibitors contain a guanidine residue (Figure 
2).  In 1969, Paolini discovered that sodium ions (Na
+
) are surrounded by three water 
molecules in aqueous media at physiological pH.  Furthermore, he found that this trihydrated 
sodium ion is analogous to the guanidine functional group (which exists as the guanidinium 
ion at physiological pH), with the trihydrated sodium ion having approximately the same 
size, shape, and charge density as the guanidinium ion (Figure 3) [12].  Thus, the 
guandine/acyl-guanidine groups found in the first four classes of NHE inhibitors (Figure 2) 
exist in the protonated form at physiological pH. 
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Figure 2. NHE Inhibitor Classifications [11] 
 
 
Figure 3.  Trihydrated Sodium vs. Guanidinium ion [12] 
 
Due to these properties guanidine is able to act as a “sodium mimic” in aqueous 
media at physiological pH, allowing it to inhibit the NHE inhibitor either by competing with 
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the sodium ion for the NHE binding sites that may overlap or by altering the sodium binding 
site [5].   
Of the four guanidine based groups, the aroylguanidines and heteroaroylguanidines 
have been studied extensively, with most emphasis on the aroylguanidine cariporide (Figure 
4) and the heteroaroylguanidine amiloride (Figure 4), along with their derivatives.  
 
Figure 4. Cariporide and Amiloride 
 
Amiloride (Figure 4) was synthesized before the discovery of NHE and has been used 
as a diuretic [11].  After the discovery of NHE, amiloride and its derivatives were among the 
only compounds used to study NHE inhibition.  Amiloride decreases vascularization of 
glioma tumors and metastasis, and thus may be useful in treating glioma tumors by 
decreasing tumor growth [9].  Furthermore, amiloride and its derivatives have been shown to 
initiate cell death in glioma cells, presumably due to their NHE inhibitory activity [8].   
However, amiloride and its derivatives also cause a number of negative side effects.  
First of all, amiloride and its derivates inhibit most forms of sodium movement across the 
cell membrane, and not NHE1 selectively [11, 13].  Inhibition concentration (i.e., IC50 for 
50% inhibition) levels for amiloride are in the micromolar range, which is too high for a 
pharmaceutical drug development.  Finally, studies have shown that amiloride can permeate 
the cell, which prevents the cell from recovering completely to steady-state pH after 
treatment and causes subsequent problems with certain enzymes.  In the end, this leads to 
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cytotoxity and kill the cell [14].  As a result, amiloride and its derivatives are unlikely 
candidates for a new cancer therapy [11].   
Cariporide (Figure 4) and its derivatives are more potent than amiloride and its 
derivatives.  Whereas amiloride has an IC50 in the micromolar range, cariporide has an IC50 
in the nanomolar range [11].  In addition, cariporide is very selective for NHE1 inhibition 
[14].  Finally, cariporide does not seem to permeate cells, thus does not cause cytotoxicity.  
Because of these reasons, cariporide is a much better pharmaceutical candidate to be 
developed for clinical use, and thus is the core structure used in the present thesis.   
1.4 Current Problem to NHE Inhibition Therapy 
 Although NHE inhibitors have been shown to be detrimental to glioma cells in vitro, 
the challenge that remains is the delivery of these compounds to the non-vascularized tissues 
of a glioma tumor.  With virtually no blood flow into the tissue (i.e., necrotic center of a 
brain tumor), it is impossible to deliver NHE inhibitors to where they need to be in order to 
combat brain cancer. 
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CHAPTER 2: RESULTS AND DISCUSSION 
2.1 A Prodrug Approach 
As a possible solution to the delivery problem of NHE inhibitors to non-vascularized 
tissues, we propose a prodrug approach (Figure 5).  In this approach, the prodrug is 
constructed of an amino acid conjugate inhibitor attached to a peptide.  The peptide will 
serve three main purposes:  
(1) It will render the amino acid conjugate inhibitor inactive as the peptide conjugate 
will be too large fit into the NHE binding site;  
(2) It will allow for transportation across the blood-brain barrier (BBB) as various 
peptides are known to transport across BBB [15];  
(3) It will allow for selective cleavage of the inhibitor-peptide bond upon 
encountering glial regions (e.g., allow for site-specific release of the active 
inhibitor) as the peptide sequence will be designed to be a substrate for glioma-
specific peptidases [16].     
 
Figure 5. Our Prodrug Approach 
 
Once the inactive prodrug has crossed the blood-brain barrier, it will remain inactive 
in the brain tissue.  Upon the mutation of a normal astrocyte into a glioma cell, the mutated 
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cell will release peptidases that are specific to glioma cells, which will in turn cleave the 
peptide from the inhibitor, thus activating the inhibitor.  Once activated, the inhibitor will 
inhibit NHE, with detrimental consequences (i.e., antiproliferation and cell death) to the 
glioma cells. The feasibility of such an approach recently has been demonstrated using 
amiloride peptide conjugates [10].  The present thesis focuses on the synthesis of an amino 
acid conjugate NHE inhibitor that can be incorporated into a peptide prodrug.   
2.2 Our Inhibitor  
In the design of our amino acid conjugate NHE inhibitor, we have chosen cariporide 
as our core structure, as it is a potent (e.g., nM IC50) and selective inhibitor of NHE.  As 
glycine is the simplest amino acid, we have chosen to incorporate it into our cariporide amino 
acid conjugate initially.   
In order to determine the point of attachment of glycine to cariporide, we examined 
the existing NHE structure-activity relationship (SAR) data available for cariporide [17].  As 
the guanidine functionality is key to NHE inhibition, it could not be altered.  SAR studies 
have also shown that substitution at C(2) and C(6) lead to loss of potency for cariporide, 
presumably due to increased steric hindrance impeding binding to NHE protein [17].  
However, substitution of the isopropyl group with an amine at C(4) does not affect the activity 
of cariporide (Figure 6).   
 
Figure 6.  C(4)-analogs of cariporide [17] 
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Thus, we decided to attach glycine at the C(4)-position.  Furthermore, our synthetic 
route allowed facile access to the C(3)-methylsulfonyl, and we decided to attach glycine at 
this position as well.  Figure 7 depicts our proposed cariporide amino acid conjugates for the 
present thesis. 
 
Figure 7. Proposed amino acid conjugates of cariporide 
 
2.3 Synthesis of C(3)-Cari-Gly 
 The synthetic route for our C(3) derivative of cariporide is depicted in Figure 8.  
Using commercially available 4-chlorobenzoic acid (1), the chlorosulfonyl group of 2 was 
installed through an electrophilic aromatic substitution [17].  In the subsequent step, the t-
butyl ester of glycine was reacted with the resultant sulfonyl chloride 2.  This reaction also 
resulted in a side product in which the carboxylic acid in 2 formed an amide by-product with 
the t-butyl ester of glycine.  To separate the two products, the reaction mixture was adjusted 
to a pH of 9-10, deprotonating the carboxylic acid in 3 (and thus rendering it water soluble) 
and allowing for selective extraction of the amide byproduct.  The reaction mixture was then 
acidified, allowing for extraction of the desired product 3 in pure form.  As we were 
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obtaining our desired product in pure form and were more interested in obtaining our C(3)-
Cari-Gly derivative, we have not currently taken any additional steps towards improving the 
yield of this reaction.  Guanidine was installed using a peptide coupling sequence.  Finally, 
the t-butyl group was removed using methanesulfonic acid to afford the desired C(3)-Cari-
Gly 4. 
 
Figure 8. Synthesis of C(3)-Cari-Gly 
 
2.4 Synthesis of C(4)-Cari-Gly 
 The synthesis of our C(4) derivative of cariporide (Figure 9) utilized a similar route as 
C(3)-Cari-Gly (Figure 8).   4-chlorobenzoic acid (1) was converted to the sulfonyl chloride 2.  
Reduction with sodium sulfite and subsequent methylation of the resultant sulfinic acid with 
methyl iodide provided 5 [17].  Unfortunately, substrate 5, which is well-poised for 
nucleophilic aromatic substitution, failed to react with the C-terminus protected glycine (t-
BuO2CCH2NH2).  Subsequent studies with various nucleophiles (discussed in Section 2.6-
2.8) showed that substrate 5 is capable of undergoing nucleophilic aromatic substitutions 
with nucleophiles stronger than t-BuO2CCH2NH2. 
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Figure 9. Synthesis of C(4)-Cari-Gly 
 
2.5 Synthesis of C(4)-Cari-Gly: Fluoro Analog Approach 
 In an attempt to make 5 (Figure 9) a better substrate for nucleophilic aromatic 
substitution, we decided to substitute the chloro group in 5 with a fluoro group (Figure 10).  
Starting with commercially available 4-fluorobenzoic acid (8), a chlorosulfonyl group was 
attached at the C(3) position, and reduced to a sulfinic acid with sodium sulfite to afford 9.  
Basic conditions converted 9 into a bis-sodium salt, setting the compound up for methylation 
to obtain 10 [17].  The ester was selectively hydrolyzed to obtain 11 (fluoro analog of 5).  
Initial reactions with t-BuO2CCH2NH2 were promising; however, unexpected purification 
problems arose.  At the time, another approach we were examining simultaneously had more 
success.  Thus, this synthetic route was put on hold. 
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Figure 10. Fluoro Analog Approach 
 
2.6 The Back-Building of Glycine: A New Approach 
 At the same time as we were attempting the fluoro analog approach (Figure 10), we 
began work on a new approach, in which we ‘back-built’ the t-butyl ester of glycine at the 
C(4) position.  Using retrosynthetic analysis, we determined we could cleave the bond to 
create the two synthons in Figure 11.  An amino group would be installed on the aromatic 
ring and subsequent SN2 alkylation reaction would ‘back-build’ glycine.  The main advantage 
of this approach is that it allowed us to use nitrogen nucleophiles which are stronger than t-
BuO2CCH2NH2. 
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        Figure 11.  Retrosynthetic Analysis 
        
 
2.7 The Back-Building Approach: A Trial 
 To test our back-building strategy (Figure 11), commercially available 4-
aminobenzoic acid (12) was alkylated with bromo-t-butylester to obtain 13.  The same 
peptide-coupling sequence as used in the synthesis of C(3)-Cari-Gly (Figure 8) was used to 
install the guanidine residue, and the t-butyl group was removed with methanesulfonic acid 
to afford 14 (Figure 12) [18]. 
 
Figure 12. Trial Back-Building 
 
2.8 Synthesis of C(4)-Cari-Gly through the Back-building Approach 
 p-Methoxybenzylamine (PMB-NH2), a better nucleophile than t-BuO2CCH2NH2, 
substituted the C(4)-chloro with ease, installing the amine at C(4) and providing 15 (Figure 
13).  Once again, the amide byproduct was observed at the carboxylic acid of 15.  The same 
acid-base extraction (as discussed in section 2.3) allowed for facile purification of 15.  
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Cleavage of the p-methoxybenzyl (PMB) group using trifluoroacetic acid (TFA) afforded 16, 
our synthetic equivalent.  Alkylation of 16 with bromo-t-butylacetate installed the t-butyl 
ester of glycine at the C(4) position to obtain 6.  Current efforts are focused on the installation 
of the guanidine residue to provide 7.  
 
Figure 13. Implementing the Back-Building Approach 
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CHAPTER 3: CONCLUSION AND FUTURE WORK 
After obtaining our C(3)-Cari-Gly and trial back-building analogs of cariporide, both 
compounds were tested for their NHE inhibition activity at the Center for Neuroscience, 
University of California, Davis.  Both C(3)-Cari-Gly and C(4)-Cari-Gly-Trial had IC50 values 
in the micromolar range (e.g., 100 !m).  As both of these compounds lack the methylsulfonyl 
moiety at the C(3) position as found in the original cariporide compound, we believe that the 
methylsulfonyl moiety is necessary at the C(3) position for NHE inhibition (Figure 14).  We 
will therefore include this moiety in all of our future inhibitors, including C(4)-Cari-Gly. 
 
Figure 14. NHE inhibitory activity of cariporide amino acid conjugates 
 
The C(4)-Cari-Gly compound (Figure 14) will soon be tested for its activity and will 
determine the path of future work.  If the compound has an appropriate IC50 value (i.e., 
nanomolar), it will be incorporated into a peptide matrix that is a substrate for glioma-
specific peptidases.  Also, the Fluoro Analog Approach (Figure 9) can be revisited to create 
an alternative synthetic route for the compound. 
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If compound 7 does not have an appropriate IC50 value, work can begin on creating an 
amino acid conjugate inhibitor using other amino acids until a nanomolar-active inhibitor is 
found.   
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CHAPTER 4: EXPERIMENTAL PROCEDURES 
 All solvents and chemicals used in this these were reagent grade and were used as 
received unless otherwise indicated.  Solvents were removed under reduced pressure (in 
vacuo) by a combination of Buchi rotary evaporator operating at ca. 25 mmHg and a Welch 
vacuum pump operating between 0.5 and 5 mmHg.  Thin layer chromatography was 
performed on precoated silica plates (Kieselgel 60 F-254).  UV active compounds were 
visualized on TLC plates by UV light (254 nm).  The TLC plates were permanently stained 
with either p-anisaldehyde in ethanol/sulfuric acid solution or with phosphomolybdic acid in 
ethanol/sulfuric acid solution.   
 NMR spectra were recorded with a JEOL ECA-500 spectrometer (1H at 500 MHz, 13C 
at 100 MHz).  Chemical shifts are reported relative to residual undeuterated CHCl3 (!7.26 
ppm for 
1
H and !77.00 ppm for 
13
C NMR), undeuterated DMSO (!2.54 ppm for 
1
H and 
!40.45 ppm for 
13
C NMR) or tetramethylsilane (!0.00 ppm for 
1
H NMR and 
13
C NMR).  
 Melting points were determined by the use of an electrothermal digital melting point 
apparatus (Mel Temp II Laboratory Devices, USA) and are uncorrected.   
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Preparation of 4-chloro-3-(chlorosulfonyl)benzoic acid [17] 
 
To chlorosulfonic acid (31.0 mL, 478.5 mmol) at 0 °C, 4-chlorobenzoic acid (1) (10.0 g, 63.8 
mmol) was added portion wise over 30 min.  The resulting reaction mixture was stirred at 
140°C for 19 h under argon.  Upon cooling to 0 °C, the reaction mixture was added dropwise 
to ice water (210 mL) and allowed to stir for 45 min.  Filtration through a sintered glass 
funnel afforded 2 as a white solid, which was used directly in the next step (see Preparation 
of 3-(N-(2-t-butoxy-2-oxoethyl)sulfamoyl)-4-chlorobenzoic acid).       
1
H NMR (DMSO-d6) 
" 7.48 (d, J = 8 Hz, 1H), 7.81 (apparent dd, 1H), 8.38 (d, J = 1.7 Hz, 1H).  
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Preparation of 3-(N-(2-t -butoxy-2-oxoethyl)sulfamoyl)-4-chlorobenzoic acid 
 
To a solution of 4-chloro-3-(chlorosulfonyl)benzoic acid (2) (1.77 g (wet), 6.93 mmol) in 
tetrahydrofuran (THF) (80 mL) at room temperature was added t-butyl ester of glycine (H-
Gly-OtBu·AcOH) (1.590 g, 8.312 mmol) and K2CO3 (3.063 g, 22.164 mmol).  The reaction 
mixture stirred at room temperature for 1.5 h.  At this time, the reaction had become a slurry, 
so more THF (20 mL) was added.  After another 1.5 h of stirring, TLC (1:1 EtOAc/Hexane 
with 0.1% acetic acid) indicated complete consumption of 2.  After removal of the solvent in 
vacuo, the residue was diluted with saturated NaHCO3 (100 mL) and H2O (30 mL) to obtain 
pH = 9-10.  Impurities were extracted with EtOAc          (2 x 100 mL).  The pH was adjusted 
to 1-2 with 10% HCl (100 mL) in an ice bath, and the resultant mixture was extracted with 
EtOAc (2 x 100 mL).  The organic layer was washed with H2O (100 mL) and saturated NaCl 
(100 mL) and dried over Na2SO4.  The solvent was removed in vacuo and the product dried 
under vacuum, resulting in 3 (0.75 g, 48% over two steps).  
1
H NMR (DMSO-d6) " 1.20 (s, 
9H), 3.70 (d, J = 6.3, 2H), 7.75 (d,         J = 8.55, 1H), 8.06 (apparent dd, 1H), 8.38 (d, J = 
1.75, 1H), 8.50 (br m, 1H); 
13
C NMR (DMSO-d6) " 27.9, 45.1, 81.6, 130.5, 131.0, 132.8, 
134.6, 136.1, 139.5, 166.1, 168.4; m.p. 148-151 °C. 
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Preparation of t-butyl 2-(2-chloro-5-(diaminomethylenecarbamoyl) 
phenylsulfonamido)acetate 
 
To a solution of 3-(N-(2-t-butoxy-2-oxoethyl)sulfamoyl)-4-chlorobenzoic acid (3) (0.20 g, 
0.572 mmol) in acetonitrile (CH3CN) (5 mL) at 0 °C was added N-hydroxysuccinimide 
(HOSu) (0.079 g, 0.686 mmol) and N,N’-dicyclohexylcarbodiimide (0.141 g, 0.686 mmol).  
The reaction mixture stirred at 0 °C for 3.5 h.  Remaining at 0 °C, the solution was filtered 
through steel wool and triethylamine (0.8 mL, 5.72 mmol) and guanidine hydrochloride 
(0.273 g, 5.86 mmol) were added to the resulting supernate.  The reaction mixture was 
warmed to room temperature and stirred for 22.5 h, after which TLC        (1:1 EtOAc/Hexane 
with 0.1% acetic acid) indicated complete consumption of 3.  After removal of the solvent in 
vacuo, the residue was diluted with H2O (50 mL) and extracted with EtOAc (100 mL).  The 
organic layer was washed with H2O (50 mL) and saturated NaCl (50 mL) and dried over 
Na2SO4.  The solvent was removed in vacuo and dried under vacuum, resulting in 3a (crude 
product).  
1
H NMR indicated purity #90 %.  Crude product used in Preparation of 2-(2-
chloro-5-(diaminomethylenecarbamoyl) 
phenylsulfonamido) acetic acid.  
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Preparation of 2-(2-chloro-5-(diaminomethylenecarbamoyl)phenylsulfonamido) 
acetic acid 
 
To a solution of t-butyl 2-(2-chloro-5-(diaminomethylenecarbamoyl)phenylsulfonamido) 
acetate (3a) (0.140 g, 0.358 mmol) in chloroform (CHCl3) (4 mL) at 0 °C was added 
methanesulfonic acid (MeSO3H) (0.1 mL, 1.542 mmol).  The reaction mixture stirred at 0 °C 
for 1.5 h and at room temperature for an additional 1.5 h, upon which TLC (1:1 
EtOAc/Hexane with 0.1% acetic acid) indicated complete consumption of 3a.  The solvent 
was removed in vacuo, resulting in an orange solid 4 (crude product).  
1
H NMR indicated 
purity # 90% which was deemed sufficient for biological testing.  
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 Preparation of 3-(chlorosulfonyl)-4-fluorobenzoic acid [17] 
 
To chlorosulfonic acid (20.0 mL, 299.5 mmol) at 0 °C, 4-fluorobenzoic acid (8) (5.00 g, 55.7 
mmol) was added portion wise over 45 min.  The resulting reaction mixture was stirred at 
150°C for 20 h under argon.  Upon cooling to 0 °C, the reaction mixture was added dropwise 
to ice water (100 mL) and allowed to stir for 45 min.  Filtration through a sintered glass 
funnel afforded 8a as a white solid (6.37 g, 74.8%).  
1
H NMR (DMSO-d6) " 7.13 (t, J = 9.15 
Hz, 1H), 7.82 (m, 1H), 8.16 (apparent dd, 1H); 13C NMR (DMSO-d6) " 117.0, 117.2, 126.7, 
130.7, 133.3, 133.3, 134.9, 135.0, 160.6, 162.6, 166.5.  
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Preparation of 4-fluoro-3-sulfinobenzoic acid [17] 
 
To a solution of sodium sulfite (Na2SO3) (31.48 g, 249.8 mmol) in H2O (61.0 mL) at room 
temperature was added portion wise 3-(chlorosulfonyl)-4-fluorobenzoic acid (8a) (34.37 g 
(wet), 99.92 mmol) over 15 min at which the reaction mixture became a slurry.  Approx. 25 
mL 32% NaOH was added to attain pH = 9, creating a heterogeneous solution, which stirred 
at room temperature for 20 h.  With TLC (1:1 EtOAc/Hexane with 0.1% acetic acid) 
indicating complete consumption of 8a, the reaction mixture was adjusted to pH = 1 with 
approx. 75 mL conc. HCl at 0 °C and extracted with EtOAc       (3 x 250 mL).  The organic 
layer was washed with saturated NaCl (2 x 250 mL) and dried over Na2SO4.  The solvent was 
removed in vacuo and the product dried under vacuum, resulting in the white sold 9 (13.47g, 
66.0%).  
1
H NMR (DMSO-d6) " 7.44 (t, J = 8.6 Hz, 1H), 8.12 (m, 1H), 8.26 (apparent dd, 
1H).  
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Preparation of sodium 4-fluoro-3-sulfinatobenzoate [17] 
 
To a solution of 4-fluoro-3-sulfinobenzoic acid (9) (2.00 g, 9.80 mmol) in H2O (10.0 mL) at 
room temperature was added NaOH (0.891 g, 22.28 mmol) to achieve pH = 10.  Solvent was 
removed in vacuo which provided a light yellow crystalline solid 9a (2.298 g, 99%), which 
was used directly in the next step (see Preparation of methyl 4-fluoro-3-
(methylsulfonyl)benzoate). 
  
  
 28 
  
Preparation of methyl 4-fluoro-3-(methylsulfonyl)benzoate [17] 
 
To a solution of sodium 4-fluoro-3-sulfinatobenzoate (9a) (1.292 g, 5.21 mmol) in 
dimethylformamide (DMF) (26.0 mL) was added methyl iodide (CH3I) (1.3 mL, 20.83 
mmol) and K2CO3 (1.00 g, enough to maintain pH = 7).  The reaction mixture stirred at 50-
60 °C under argon for 5 h, upon which TLC (1:1 EtOAc/Hexane with 0.1% acetic acid) 
indicated complete consumption of 9a.  CH3I was distilled at 50-60 °C using a short path 
distillation apparatus.  The remaining reaction mixture was poured into ice water.  Filtration 
through a sintered glass funnel afforded 10 as a white solid (0.500 g, 41.3%). 
1
H NMR 
(DMSO-d6) " 3.36 (s, 3H), 3.86 (s, 3H), 7.64 (s, 1H), 8.30 (s, 2H); 13C NMR (DMSO-d6) "  
44.0, 53.3, 118.8, 119.0, 127.2, 129.2, 129.3, 131.0 137.9, 138.0, 161.0, 163.1, 164.6; m.p. 
108-110 °C. 
 
  
  
 29 
  
Preparation of 4-fluoro-3-(methylsulfonyl)benzoic acid 
 
To a solution of methyl 4-fluoro-3-(methylsulfonyl)benzoate (10) (0.500 g, 2.15 mmol) in 
THF (10.8 mL) at 0 °C was added lithium hydroxide monohydrate (LiOH·H2O) (0.289 g, 
6.89 mmol).  The reaction mixture stirred at 0 °C for 23 h, upon which TLC (1:1 
EtOAc/Hexane with 0.1% acetic acid) indicated complete consumption of 10.  The solvent 
was removed in vacuo and the resulting residue was quenched with H2O (15 mL) resulting in 
a pH = 9.  Impurities were removed by extraction with EtOAc (3 x 15 mL).  The pH of the 
reaction mixture was adjusted to 1-2 at 0 °C with approx. 3 mL 10% HCl and extracted with 
EtOAc (3 x 15 mL).  The organic layer was washed with H2O (15 mL) and saturated NaCl 
(15 mL) and dried over Na2SO4.  The solvent was removed in vacuo and the product dried 
under vacuum, resulting in 11 (0.323 g, 68.9%).  
1
H NMR (DMSO-d6) " 3.35 (s, 1H), 7.59 
(t, J = 9.15 Hz, 1H), 8.26 (m, 1H), 8.32 (apparent dd, 1H); 13C NMR (DMSO-d6) " 44.0, 
118.5, 118.7, 128.4, 129.0, 129.1, 131.1, 138.0, 138.1, 160.8, 162.9, 165.7; m.p. 207-210 °C. 
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Preparation of 4-(2-t-butoxy-2-oxoethylamino)benzoic acid [18] 
 
To a solution of 4-aminobenzoic acid (12) (1.0 g, 7.29 mmol) in DMF (48.6 mL) at 0 °C was 
added t-butyl 2-bromoacetate (1.71 g, 8.75 mmol) and LiH (0.133 g, 16.77 mmol).  The 
reaction mixture stirred at room temperature for 21 h under argon, upon which TLC (1:1 
EtOAc/Hexane with 0.1% acetic acid) indicated complete consumption of 12.  The reaction 
was quenched with H2O (50 mL) and 10% HCl (5 mL) was added to pH = 1.  The product 
was extracted with EtOAc (2 x 100 mL).  The organic layer was washed with H2O (2 x 100 
mL) and saturated NaCl (100 mL) and dried over Na2SO4.  The solvent was removed in vacuo 
and the product dried under vacuum, resulting in 13 as a white solid (0.88 g, 48%).  
1
H NMR 
(DMSO-d6) " 1.38 (s, 9H), 4.62 (s, 2H), 6.10 (br s, 2H), 6.62 (d, J = 8.6, 2H) 7.68 (d, J = 8.6, 
2H); 
13
C NMR (DMSO-d6) " 28.2, 61.3, 81.9, 113.8, 116.2, 131.9, 153.5, 165.8, 167.7; m.p. 
63-68 °C. 
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Preparation of t-butyl 2-(4-(diaminomethylenecarbamoyl)phenylamino)acetate [18] 
 
To a solution of 4-(2-t-butoxy-2-oxoethylamino)benzoic acid (13) (0.20 g, 0.796 mmol) in 
acetonitrile (CH3CN) (5.3 mL) at 0 °C was added N-hydroxysuccinimide (HOSu) (0.09 g, 
0.793 mmol) and N,N’-dicyclohexylcarbodiimide (0.16 g, 0.793 mmol).  The reaction 
mixture stirred at 0 °C for 4 h.  Remaining at 0 °C, the solution was filtered through glass 
wool and triethylamine (1.1 mL, 7.93 mmol) and guanidine hydrochloride (0.38 g, 3.97 
mmol) were added to the resulting supernate.  The reaction mixture was warmed to room 
temperature and stirred for 21 h, after which TLC (1:1 EtOAc/Hexane with 0.1% acetic acid) 
indicated complete consumption of 13.  After removal of the solvent in vacuo, the residue 
was diluted with H2O (50 mL) and extracted with EtOAc (100 mL).  The organic layer was 
washed with H2O (50 mL) and saturated NaCl (50 mL) and dried over Na2SO4.  The solvent 
was removed in vacuo and dried under vacuum, resulting in 13a (0.28 g, wet and slightly 
impure). The purity was deemed sufficient       (# 90% by 
1
H NMR) for use in the next step 
(see Preparation of 2-(4-(diaminomethylene carbamoyl)phenylamino)acetic acid). 
1
H NMR 
(CDCl3) " 1.48 (s, 9H), 4.75 (s, 2H), 7.45 (d, J = 8.6, 2H), 8.19 (m, 2H). 
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Preparation of 2-(4-(diaminomethylenecarbamoyl)phenylamino)acetic acid [18] 
 
A solution of t-butyl 2-(4-(diaminomethylenecarbamoyl)phenylamino)acetate (13a)    (1.0 g, 
3.97 mmol) in methanesulfonic acid (MeSO3H) (10 mL) was stirred under argon at  150 °C 
for 16.5 h, upon which TLC (1:1 EtOAc/Hexane with 0.1% acetic acid) indicated complete 
consumption of 13a.  The reaction mixture was quenched with H2O (60 mL) and extracted 
with EtOAc (70 mL).  The organic layer was washed with H2O (35 mL) and saturated NaCl 
(30 mL) and dried over Na2SO4.  The solvent was removed in vacuo. Chloroform (20 mL) 
was added to the resultant solid and removed in vacuo to azeotrope the remaining EtOAc, 
resulting in an solid 4 (crude product).  
1
H NMR indicated purity  # 90% which was deemed 
sufficient for biological testing.  
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Preparation of 4-chloro-3-sulfinobenzoic acid [17] 
 
To a solution of 4-chloro-3-(chlorosulfonyl)benzoic acid (2) (73.55 g , 191.6 mmol) in H2O 
(110 mL) at 0 °C was added sodium sulfite (Na2SO3) (60.37 g, 479 mmol).  32% NaOH was 
added to attain pH = 9, and the reaction was stirred at room temperature for 18.5 h after 
which a color change from dark brown to light brown had occurred.  The reaction mixture 
was adjusted to pH = 1 with 10% HCl (225 mL) at 0 °C upon which a precipitate formed.  
The precipitate was filtered, resulting in the off-white sold 2a (30.0 g wet) which was used 
directly in the next step (see Preparation of 4-chloro-3-(methyl sulfonyl)benzoic acid). 
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Preparation of 4-chloro-3-(methylsulfonyl)benzoic acid [17] 
 
To a solution of 4-chloro-3-sulfinobenzoic acid (2a) (9.0 g , 57.6 mmol) in H2O (36 mL) and 
methanol (CH3OH) (36 mL) at room temperature was added 32% NaOH to attain  pH = 9 
and iodomethane (CH3I) (24 mL, 380.2 mmol).  The reaction was stirred at 50 °C for 30 h, 
maintaining a pH = 9-10 with occasional addition of 32% NaOH.  The reaction mixture was 
quenched with ice water (120 mL) and filtered.  The supernatant was adjusted to pH = 1 with 
conc. HCl at 0 °C, upon which a white precipitate formed.  The precipitate was filtered, 
resulting in the off-white sold 2a (1.6 g, 11.8%).  
1
H NMR (DMSO-d6) " 3.38 (s, 3H), 7.82 
(d, J = 8 Hz, 1H), 8.16 (d, J = 7.45, 1H), 8.48 (s, 1H). 
13
C NMR (DMSO-d6) " 42.8, 131.1, 
131.5, 133.1, 136.0, 136.3, 138.8, 165.8. 
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Preparation of 4-(4-methoxybenzylamino)-3-(methylsulfonyl)benzoic acid 
 
To para-methoxybenzylamine (7.26 mL, 55.9 mmol) was added 4-chloro-3-
(methylsulfonyl)benzoic acid (2) (0.88 g, 3.75 mmol) at room temperature.  The reaction 
mixture was stirred at 150 °C for 2.75 h under argon, upon which TLC (EtOAc with 0.1% 
acetic acid) showed complete consumption of 2.  At 0 °C, 1M NaOH (100 mL) was added to 
the reaction mixture and stirred for 15 min.  Impurities were extracted with EtOAc (2 x 100 
mL).  The pH of the aqueous was adjusted to 1-2 with conc. HCl (approx. 16 mL) at 0 °C and 
extracted with EtOAc (3 x 100 mL).  The organic layer was washed with H2O (75 mL) and 
saturated NaCl (75 mL) and dried over Na2SO4.  The solvent was removed in vacuo and the 
product dried under vacuum, resulting in 16 (0.77 g, 61.3%).   
1
H NMR (DMSO-d6) " 3.20 
(s, 3H), 3.68, (s, 3H), 4.44 (d, J = 5.75, 2H), 6.81 (d, J = 9.2, 1H), 6.87 (d, 8.6, 2H), 7.16 (t, J 
= 5.75, 1H), 7.27 (d, J = 8.6, 2H), 7.86 (apparent dd, 1H), 8.19 (d, J = 1.7, 1H); 
13
C NMR 
(DMSO-d6) " 42.7, 46.0, 55.5, 113.1, 114.5, 117.9, 121.4, 128.9, 130.5, 132.2, 136.3, 149.5, 
159.0, 166.8; m.p. 212-218 °C. 
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Preparation of 4-amino-3-(methylsulfonyl)benzoic acid 
 
To trifluoroacetic acid (12 mL, 134.63 mmol) was added 4-(4-methoxybenzylamino)-3-
(methylsulfonyl)benzoic acid (15) (1.00 g, 2.99 mmol) at room temperature.  The reaction 
mixture was stirred at 55 °C for 20 min under argon, upon which TLC (EtOAc with 0.1% 
acetic acid) showed complete consumption of 15.  The solution was poured into 1M NaOH 
(150 mL) at 0 °C to obtain pH = 10 and extracted with EtOAc (3 x 150 mL) to remove 
impurities.  The pH of the aqueous was adjusted to 1-2 with conc. HCl (approx. 8 mL) at 0 
°C and extracted with EtOAc (3 x 150 mL).  The organic layer was washed with H2O (150 
mL) and saturated NaCl (150 mL) and dried over Na2SO4.  The solvent was removed in 
vacuo and the product dried under vacuum, resulting in 16 (0.649 g, quantitative).  
1
H NMR 
(DMSO-d6) " 3.11 (s, 3H), 6.70 (br s, 2H), 6.88 (d, J = 8.6, 1H), 7.81 (t, J = 8 Hz, 1H), 8.11 
(s, 1H); 
13
C NMR (DMSO-d6) " 42.5, 117.3, 118.0, 120.0, 132.1, 135.8, 151.1, 166.9; m.p. 
246-250 ºC. 
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Preparation of 4-(2-t-butoxy-2-oxoethylamino)-3-(methylsulfonyl)benzoic acid 
 
To a solution of 4-amino-3-(methylsulfonyl)benzoic acid (16) (0.500 g, 2.32 mmol) in DMF 
(15.5 mL) was added lithium hydride (LiH) (0.051 g, 6.51 mmol) and bromo-t-butylacetate 
(0.589 g, 3.02 mmol) at 0 °C.  The reaction mixture was stirred at 0 °C for   2 h under argon, 
upon which TLC (EtOAc with 0.1% acetic acid) showed complete consumption of 16.  The 
solution was quenched with saturated NH4Cl (50 mL) to obtain pH = 7 and extracted with 
CH2Cl2 (3 x 50 mL).  The organic layer was washed with H2O (75 mL) and saturated NaCl 
(75 mL) and dried over Na2SO4.  The solvent was removed in vacuo and the product dried 
under vacuum, resulting in 6 (0.75 g, 98.2%).  
1
H NMR (CDCl3) " 1.39 (s, 9H), 3.14 (s, 3H), 
3.30 (s, 2H), 6.86 (br s, 2H) 6.91 (d, J = 8.55, 1H), 7.84 (t, J = 8.6, 1H), 8.16 (d, J = 1.7, 1H); 
13
C NMR (CDCl3) " 28.1, 42.8, 61.6, 82.7, 117.2, 118.8, 121.0, 132.8, 136.5, 150.1, 164.7, 
167.1; m.p. 163-165 ºC. 
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Appendix A. 
1
H NMR Spectra of 4-chloro-3-(chlorosulfonyl)benzoic acid 
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Appendix B. 
1
H NMR Spectra of 3-(N-(2-t -butoxy-2-oxoethyl)sulfamoyl)-4-chlorobenzoic 
acid  
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Appendix C. 
13
C NMR Spectra of 3-(N-(2-t -butoxy-2-oxoethyl)sulfamoyl)-4-chlorobenzoic 
acid  
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Appendix D. 
1
H NMR Spectra of t-butyl 2-(2-chloro-5-(diaminomethylenecarbamoyl) 
phenylsulfonamido)acetate  
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Appendix E. 
1
H NMR Spectra of 2-(2-chloro-5-(diaminomethylenecarbamoyl) 
phenylsulfonamido)acetic acid 
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Appendix F. 
1
H NMR Spectra of 3-(chlorosulfonyl)-4-fluorobenzoic acid 
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Appendix G. 
13
C NMR Spectra of 3-(chlorosulfonyl)-4-fluorobenzoic acid 
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Appendix H. 
1
H NMR Spectra of 4-fluoro-3-sulfinobenzoic acid 
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Appendix I. 
1
H NMR Spectra of methyl 4-fluoro-3-(methylsulfonyl)benzoate 
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Appendix J. 
13
C NMR Spectra of methyl 4-fluoro-3-(methylsulfonyl)benzoate 
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Appendix K. 
1
H NMR Spectra of 4-fluoro-3-(methylsulfonyl)benzoic acid 
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Appendix L. 
13
C NMR Spectra of 4-fluoro-3-(methylsulfonyl)benzoic acid 
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Appendix M. 
1
H NMR Spectra of 4-(2-t-butoxy-2-oxoethylamino)benzoic acid 
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Appendix N. 
13
C NMR Spectra of 4-(2-t-butoxy-2-oxoethylamino)benzoic acid 
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Appendix O. 
1
H NMR Spectra of t-butyl 2-(4-(diaminomethylenecarbamoyl) 
phenylamino)acetate 
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Appendix P. 
1
H NMR Spectra of 2-(4-(diaminomethylenecarbamoyl)phenylamino)acetic 
acid 
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Appendix Q. 
1
H NMR Spectra of 4-chloro-3-(methylsulfonyl)benzoic acid 
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Appendix R. 
13
C NMR Spectra of 4-chloro-3-(methylsulfonyl)benzoic acid 
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Appendix S. 
1
H NMR Spectra of 4-(4-methoxybenzylamino)-3-(methylsulfonyl)benzoic 
acid 
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Appendix T. 
13
C NMR Spectra of 4-(4-methoxybenzylamino)-3-(methylsulfonyl) benzoic 
acid 
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Appendix U. 
1
H NMR Spectra of 4-amino-3-(methylsulfonyl)benzoic acid 
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Appendix V. 
13
C NMR Spectra of 4-amino-3-(methylsulfonyl)benzoic acid 
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Appendix W. 
1
H NMR Spectra of 4-(2-t-butoxy-2-oxoethylamino)-3-(methylsulfonyl) 
benzoic acid 
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Appendix X. 
13
C NMR Spectra of 4-(2-t-butoxy-2-oxoethylamino)-3-(methylsulfonyl) 
benzoic acid 
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